PROVE-HF (NCT02887183) is a 12-month prospective, single-arm, open-label trial investigating the correlation between changes in NT-proBNP and long-term changes in cardiac remodeling measures after the initiation of sacubitril/valsartan in patients with HFrEF. Here, NPPB is linked to hydrops fetalis.